

Your doctor is the best resource for medical advice and information. The health information contained herein is provided for educational/awareness purposes only and is not intended to replace discussions with a medical practitioner and/or medical advice or be construed as a promotional information.

Package Leaflet: Information for the user

Lorlatinib Tablets

LORBRIQUA®

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- If you have any further questions, ask your doctor.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Lorbriqua (Lorlatinib) is and what it is used for
2. What you need to know before you take Lorbriqua (Lorlatinib)
3. How to take Lorbriqua (Lorlatinib)
4. Possible side effects
5. How to store Lorbriqua (Lorlatinib)
6. Contents of the pack and other information

1. What Lorbriqua (Lorlatinib) is and what it is used for

Lorbriqua (Lorlatinib) contains the active substance Lorlatinib, which is a kinase inhibitor. It is used to treat adult patients with metastatic (tumor has spread to other parts of the body) non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

If you have any questions about how Lorbriqua (Lorlatinib) works or why this medicine has been prescribed for you, ask your doctor.

® Trademark Proprietor: Pfizer Inc., USA,
Licensed User: Pfizer Products India Private Limited, India

2. What you need to know before you take Lorbriqua (Lorlatinib)

Do not take Lorbriqua (Lorlatinib)

- If you are allergic to lorlatinib or any of the other ingredients of Lorbriqua (Lorlatinib) (listed in section 6). If you are on certain medication known as strong CYP3A inducers (tell your doctor all the medication you are taking).

Warnings and precautions

Talk to your doctor before taking Lorbriqua (Lorlatinib):

- **If you are simultaneously using strong CYP3A inducers.** Lorbriqua (Lorlatinib) causes severe liver toxicity if consumed simultaneously with CYP3A inducers. Your doctor may check your alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level during treatment with Lorbriqua (Lorlatinib).
- **If you have central nervous system effects.** Treatment with Lorbriqua (Lorlatinib) may lead to seizures, psychotic effects and changes in cognitive function, mood (including suicidal ideation), speech, mental status, and sleep. Your doctor may withhold and resume at the same dose or at a reduced dose or permanently discontinue Lorbriqua (Lorlatinib) based on severity.
- **If your serum cholesterol and triglycerides increase.** Lorbriqua (Lorlatinib) can increase serum cholesterol and triglycerides. Your doctor may initiate or increase the dose of lipid-lowering agents. Your doctor may withhold and resume at the same dose for the first occurrence; resume at the same or a reduced dose of Lorlatinib for recurrence based on severity.
- **If you have atrioventricular (AV) block.** Lorbriqua (Lorlatinib) can cause AV Block. Your doctor may monitor ECG prior to initiating Lorbriqua (Lorlatinib) and periodically thereafter; and withhold and resume at a reduced dose or at the same dose in patients who undergo pacemaker placement. Permanently discontinue for recurrence in patients without a pacemaker.
- **If you have shortness of breath, cough, fever.** Call your doctor immediately if you get symptoms such as breathlessness, weakness, cough, raise in temperature while on treatment with Lorbriqua (Lorlatinib).
- **If you have high blood pressure.** Lorbriqua (Lorlatinib) can raise blood pressure. Your doctor may check your blood pressure during treatment with Lorbriqua (Lorlatinib), and you may be treated with medicines to reduce the blood pressure, if needed.
- **If you have high blood sugar.** Lorbriqua (Lorlatinib) can raise blood sugar. Your doctor may check your blood sugar during treatment with Lorbriqua (Lorlatinib), and you may be treated with medicines to reduce the blood sugar, if needed.

Other medicines and Lorbriqua (Lorlatinib)

Tell your doctor if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription and even those not prescribed.

Some medicines can affect the levels of Lorbriqua (Lorlatinib) in your body. You should inform your doctor if you are taking any medicines that falls under the following category:

- CYP3A inducers like, rifampicin, modafinil and St. John's wort,
- Fluconazole,
- CYP3A substrates like – midazolam,
- CYP2C9 Substrates like tolbutamide,
- CYP2B6 Substrates like bupropion,
- UGT1A Substrates like acetaminophen,
- P-glycoprotein substrates like fexofenadine,
- CYP3A inhibitor like itraconazole.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.

If you might get pregnant, you should use a reliable method of contraception during treatment with Lorbriqua (Lorlatinib).

Lorbriqua (Lorlatinib) can cause fetal harm when administered to a pregnant woman. Your doctor may advise pregnant women of the potential risk to a fetus and females of reproductive potential to use an effective non-hormonal method of contraception, since Lorbriqua (Lorlatinib) can render hormonal contraceptives ineffective, during treatment with Lorbriqua (Lorlatinib) and for at least 6 months after the final dose. Your doctor may advise males with female partners of reproductive potential to use effective contraception during treatment with Lorbriqua (Lorlatinib) and for at least 3 months after the final dose.

If you are breast-feeding, tell your doctor. You should not breast-feed during treatment with Lorbriqua (Lorlatinib) and for 7 days after the final dose.

Fertility

Lorbriqua (Lorlatinib) may transiently impair male fertility.

Driving and using machines

Though there is no data on effects of Lorlatinib on ability to drive and use machines, caution should be exercised.

3. How to take Lorbriqua (Lorlatinib)

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

The recommended dosage of Lorbriqua (Lorlatinib) is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact. Take Lorbriqua (Lorlatinib) at the same time each day. Do not take an additional dose if vomiting occurs after Lorbriqua (Lorlatinib) but continue with the next scheduled dose.

If you have side effects, the recommended dose reductions are:

- First dose reduction: Lorbriqua (Lorlatinib) 75 mg orally once daily
- Second dose reduction: Lorbriqua (Lorlatinib) 50 mg orally once daily

If you are unable to tolerate 50 mg once a day, your doctor will stop Lorbriqua (Lorlatinib). Your doctor will determine the appropriate dose you need to take, as well as if and when you need to stop treatment with Lorbriqua (Lorlatinib).

Tell your doctor about all the medicines you take, including prescription medicines, over the counter medicines, vitamins, and herbal supplements. Taking Lorbriqua (Lorlatinib) with certain other medicines may increase your risk of side effects and may affect the way Lorbriqua (Lorlatinib) or the other medicines work. The dose might be modified by the doctor as required.

If you have severe liver problems (Child-Pugh C) inform your doctor. The recommended dose for severe liver problems is 50 mg orally once daily.

If you have kidney problems, inform your doctor. For the patient with creatinine clearance 15 to < 30 mL/min, the recommended dose is 75 mg orally once daily.

If you take more Lorbriqua (Lorlatinib) than you should

If you have accidentally taken too many tablets, talk to your doctor straight away. You may require medical attention.

If you forget to take Lorbriqua (Lorlatinib)

If a dose is missed, then take the missed dose unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You must immediately contact your doctor if you experience any of those serious side effects (see also **What you need to know before you take Lorbriqua (Lorlatinib)**):

- Risk of serious liver toxicity with concomitant use of strong CYP3A inducers
- Central nervous system effects include seizures, psychotic effects and changes in cognitive function, mood (including suicidal ideation), speech, mental status, and sleep
- Increased serum cholesterol and triglyceride levels
- AV Block
- Inflammation of lung tissues
- Increased blood pressure
- Increased blood sugar

5. How to store Lorbriqua (Lorlatinib)

- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on carton, bottle and blister foil after “Expiry”. The expiry date refers to the last day of that month.
- Store below 30°C.
- Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.

Do not throw away any medicines via wastewater or household waste. Ask your doctor how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Lorbriqua (Lorlatinib) contains

Lorbriqua (Lorlatinib) 25 mg film-coated tablets

The active substance is Lorlatinib. Each film-coated tablet contains Lorlatinib 25 mg. The other ingredients are:

- *Tablet core contains:* Microcrystalline cellulose, Dibasic calcium phosphate anhydrous, Sodium starch glycolate, Magnesium stearate.
- *Coloured film-coating contains:* Hydroxypropyl methylcellulose (HPMC)/Hypromellose, Lactose monohydrate, Macrogol 4000/PEG 3350, Triacetin, Titanium dioxide, Black iron oxide, Iron oxide red.

Lorbriqua (Lorlatinib) 100 mg film-coated tablets

The active substance is Lorlatinib. Each film-coated tablet contains lorlatinib 100 mg. The other ingredients are:

- *Tablet core contains:* Microcrystalline cellulose, Dibasic calcium phosphate anhydrous, Sodium starch glycolate, Magnesium stearate.
- *Coloured film-coating contains:* Hydroxypropyl methylcellulose (HPMC)/Hypromellose, Lactose monohydrate, Macrogol 4000/PEG 3350, Triacetin, Titanium dioxide, Black iron oxide, Iron oxide red.

What Lorbriqua (Lorlatinib) looks like and contents of the pack

Lorbriqua (Lorlatinib) 25 mg is supplied as 8 mm round, tan, immediate release, film-coated, debossed with “Pfizer” on one side and “25” and “LLN” on the other.

Lorbriqua (Lorlatinib) 100 mg is supplied as 8.5 mm × 17 mm oval, lavender, immediate release, film-coated, debossed with “Pfizer” on one side and “LLN 100” on the other side.

25 mg: Carton with 3 blister strips, 10 tablets each and Carton with 3 blister strips, 5 tablets each

100 mg: Carton with 3 blister strips, 10 tablets each and Carton with 3 blister strips, 5 tablets each

25 mg or 100 mg: HDPE Bottle of 30 tablets, each

All strengths/pack sizes mentioned in this document might not be available in the market.

Imported and marketed by

Pfizer Products India Private Limited,
The Capital- B Wing, 1802, 18th Floor,
Plot No. C-70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051,
India

Manufacturer

M/s. Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1,
Freiburg – 79090, Germany

This leaflet was prepared based on LPD no. LPDLOR02026.